Difference between revisions of "Adenosquamous carcinoma of the lung"
Jump to navigation
Jump to search
| Line 5: | Line 5: | ||
==General== | ==General== | ||
*Rare. | *Rare. | ||
*Respond to [[tyrosine kinase inhibitors]].<ref name=pmid23769878>{{Cite journal | last1 = Song | first1 = Z. | last2 = Lin | first2 = B. | last3 = Shao | first3 = L. | last4 = Zhang | first4 = Y. | title = Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. | journal = J Chin Med Assoc | volume = 76 | issue = 9 | pages = 481-5 | month = Sep | year = 2013 | doi = 10.1016/j.jcma.2013.05.007 | PMID = 23769878 }}</ref><ref | *Respond to [[tyrosine kinase inhibitors]].<ref name=pmid23769878>{{Cite journal | last1 = Song | first1 = Z. | last2 = Lin | first2 = B. | last3 = Shao | first3 = L. | last4 = Zhang | first4 = Y. | title = Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. | journal = J Chin Med Assoc | volume = 76 | issue = 9 | pages = 481-5 | month = Sep | year = 2013 | doi = 10.1016/j.jcma.2013.05.007 | PMID = 23769878 }}</ref><ref name=pmid23037472>{{Cite journal | last1 = Iwanaga | first1 = K. | last2 = Sueoka-Aragane | first2 = N. | last3 = Nakamura | first3 = T. | last4 = Mori | first4 = D. | last5 = Kimura | first5 = S. | title = The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib. | journal = Intern Med | volume = 51 | issue = 19 | pages = 2771-4 | month = | year = 2012 | doi = | PMID = 23037472 }}</ref> | ||
==Microscopic== | ==Microscopic== | ||
Revision as of 01:45, 9 April 2014
Adenosquamous carcinoma of the lung is a rare epithelial derived malignancy of the lung with features of both adenocarcinoma and squamous cell carcinoma.
It is grouped with the non-small cell lung cancers.
General
- Rare.
- Respond to tyrosine kinase inhibitors.[1][2]
Microscopic
Features:
- Adenocarcinoma component.
- Squamous cell carcinoma component.
See also
References
- ↑ Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.
- ↑ Iwanaga, K.; Sueoka-Aragane, N.; Nakamura, T.; Mori, D.; Kimura, S. (2012). "The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.". Intern Med 51 (19): 2771-4. PMID 23037472.